BEIJING - Simcere Pharmaceutical Group posted lower-than-forecast earnings for 2008 due to the country's low rate of insurance coverage, combined with patients' cutting back on medical expenditures in the wake of the global recession, according to a senior executive
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
